Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Short Interest Update

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) saw a large decrease in short interest in the month of May. As of May 15th, there was short interest totalling 52,700 shares, a decrease of 37.4% from the April 30th total of 84,200 shares. Currently, 2.5% of the company’s shares are sold short. Based on an average daily volume of 250,100 shares, the days-to-cover ratio is presently 0.2 days.

Salarius Pharmaceuticals Stock Performance

Shares of SLRX traded down $0.01 during trading hours on Friday, hitting $0.78. The stock had a trading volume of 29,601 shares, compared to its average volume of 1,283,495. The firm has a market cap of $1.66 million, a P/E ratio of -0.10 and a beta of 0.42. The company’s fifty day simple moving average is $0.75 and its 200 day simple moving average is $1.31. Salarius Pharmaceuticals has a 12-month low of $0.45 and a 12-month high of $7.20.

Salarius Pharmaceuticals (NASDAQ:SLRX) last issued its earnings results on Wednesday, May 14th. The company reported ($1.03) earnings per share for the quarter, topping the consensus estimate of ($2.40) by $1.37.

About Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.